Leap Therapeutics Inc
LPTX2.050USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
84.95MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Leap Therapeutics Inc Unternehmen
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc Informationen
BörsenkürzelLPTX
Name des UnternehmensCypherpunk Technologies Inc
IPO-datumJan 24, 2017
CEOOnsi (Douglas E)
Anzahl der mitarbeiter52
WertpapierartOrdinary Share
GeschäftsjahresendeJan 24
Addresse47 Thorndike Street
StadtCAMBRIDGE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02142
Telefon16172524343
Websitehttps://www.leaptx.com/
BörsenkürzelLPTX
IPO-datumJan 24, 2017
CEOOnsi (Douglas E)
Führungskräfte von Leap Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
--
--
Mr. Mark O'Mahony
Mr. Mark O'Mahony
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Mon, Jan 5
Aktualisiert: Mon, Jan 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
Andere
59.09%
Aktionäre
Aktionäre
Anteil
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
Andere
59.09%
Aktionärstypen
Aktionäre
Anteil
Family Office
14.62%
Corporation
11.53%
Individual Investor
11.07%
Investment Advisor
6.53%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
Andere
48.65%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
109
9.04M
15.96%
-11.00M
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Winklevoss Capital Management, LLC
8.28M
14.62%
+8.28M
--
Oct 24, 2025
Severns (Sean Michael)
6.00M
10.59%
+6.00M
--
Nov 12, 2025
Gilead Sciences Inc
5.32M
9.39%
--
--
Oct 24, 2025
The Vanguard Group, Inc.
1.16M
2.05%
--
--
Sep 30, 2025
BofA Global Research (US)
1.44M
2.55%
+1.44M
+451295.63%
Sep 30, 2025
Acadian Asset Management LLC
1.24M
2.18%
--
--
Sep 30, 2025
Beigene Ltd
1.22M
2.15%
+1.22M
--
Oct 31, 2024
Simplify Asset Management Inc
975.61K
1.72%
+118.25K
+13.79%
Sep 30, 2025
HealthCare Ventures LLC
676.32K
1.19%
-20.91K
-3.00%
Oct 24, 2025
Geode Capital Management, L.L.C.
312.19K
0.55%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
Anteil0.37%
iShares Micro-Cap ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
